CVS Health Reports Strong Q2 2025 Results, Updates Full-Year Guidance
CVS Health Corporation reported a significant increase in revenue for Q2 2025, surpassing expectations.
BTC$61,703.00-1.60%
ETH$1,651.63-1.20%
USDT$0.99870.00%
USDC$0.9998+0.01%
XRP$1.08-1.71%
SOL$69.04-0.43%
TRX$0.3287-0.47%
FIGR_HELOC$1.03-0.65%
HYPE$63.55+2.01%
DOGE$0.0771-2.40%
USDS$0.9998+0.01%
RAIN$0.0159+1.39%
LEO$9.34-2.18%
ZEC$416.47+0.32%
XLM$0.1857-3.09%
BTC$61,703.00-1.60%
ETH$1,651.63-1.20%
USDT$0.99870.00%
USDC$0.9998+0.01%
XRP$1.08-1.71%
SOL$69.04-0.43%
TRX$0.3287-0.47%
FIGR_HELOC$1.03-0.65%
HYPE$63.55+2.01%
DOGE$0.0771-2.40%
USDS$0.9998+0.01%
RAIN$0.0159+1.39%
LEO$9.34-2.18%
ZEC$416.47+0.32%
XLM$0.1857-3.09%
Mastercard's Q2 2025 results exceeded expectations with significant growth in revenue and earnings per share.
CVS Health Corporation reported a significant increase in revenue for Q2 2025, surpassing expectations.
Comcast's second quarter of 2025 highlighted strong financial results with a notable increase in earnings per share and revenue.
Spotify’s impressive growth tripped over higher personnel costs. Is this a temporary stumble or a prime buying opportunity?
Garmin's Q2 2025 results reveal strong performance, with significant growth across all segments, surpassing market expectations.
Altria's Q2 2025 results show a decline in net revenues yet an improvement in adjusted EPS, surpassing expectations.
ADP's fourth quarter performance exceeded expectations with a notable increase in revenue and earnings per share.
Humana Inc. reports second quarter 2025 financial results with earnings per share (EPS) slightly below expectations.
For near-future practical quantum computing, these companies offer relatives safe exposure. And some more than others.
Procter & Gamble has posted a solid performance in the fourth quarter of 2025, with net sales and earnings per share exceeding expectations.
UnitedHealth Group shares fell over 5% in premarket trading after missing Q2 earnings expectations and providing disappointing 2025 guidance.
Merck's second-quarter performance showed a slight decline in sales compared to the previous year.
UnitedHealth Group's second-quarter results showed a revenue increase but a decline in earnings per share compared to expectations.